Using Bartonella henselae isolates from cats and a human, the activity of pradofloxacin was compared with those of enrofloxacin and azithromycin. By Etest and disc diffusion assay, pradofloxacin showed greater antimicrobial activity than did other antibiotics. We conclude that pradofloxacin may prove useful for the treatment of B. henselae infections.
Bartonella henselae is the causative agent of cat scratch disease (CSD) and is also involved in numerous other clinical presentations, including endocarditis, bacillary angiomatosis, and peliosis hepatitis in immunocompromised patients (1, 3) . Cats are the main reservoir for B. henselae (4) . In people, CSD typically does not respond to antibiotic therapy; therefore, the recommendation to treat CSD patients with azithromycin or other antibiotics remains controversial (8) . Quinolones are used extensively for the treatment of bacterial infections in human and veterinary medicine (5) . Pradofloxacin, an expanded-spectrum fluoroquinolone, is being developed exclusively for use in veterinary medicine (10) . Enrofloxacin is a broad-spectrum antimicrobial agent with bactericidal activity against Gramnegative and Gram-positive bacteria (6, 9) .
Currently, treatment recommendations for companion animals and humans infected with B. henselae are based primarily on outcome assessments from a few case reports and limited data from treatment trails in cats or humans (8) . As in vitro pradofloxacin and enrofloxacin susceptibility data for B. henselae have not been reported yet, the primary objectives of this study were to test the same isolates for susceptibility to fluoroquinolones and to determine the comparative in vitro activities of azithromycin, enrofloxacin, and pradofloxacin by using a disc diffusion assay.
Nine Bartonella henselae isolates (Table 1) were collected from cats from the United States. Four isolates (Mina Mia, Bh94FO73, BhFO1946, and BhFO2112) were from healthy cats and another four isolates (Bh95FO101, BhFO2221, BhFO2424, and BhFO3021) were from sick cats. Isolate Stray7 was from a stray North Carolina cat. BhHI is the ATCC type strain obtained by blood culture from a febrile, HIV-infected patient in Houston, TX. Etest strips and diffusion discs of pradofloxacin (5 g) and enrofloxacin (5 g) were purchased from AB Biodisk (Solna, Sweden) and supplied by Bayer HealthCare, Germany, and azithromycin (15 g) discs were purchased from VWR International. B. henselae isolates were grown on Columbia 5%
sheep blood agar plates and incubated at 37°C in a 5% CO 2 -enriched atmosphere. Susceptibility testing using an Etest strip was carried out following subinoculation. Plates were observed daily for the presence or absence of bacterial growth adjacent to the Etest strip. Selection of antibiotic-resistant mutants was performed using disc diffusion assay by serial passages of B. henselae in blood agar plates containing a disc of antibiotic (pradofloxacin, enrofloxacin, and azithromycin) initially placed in the corner of the plate. The plates were incubated at 37°C, and diameters of growth inhibition (in mm) were measured every 2 weeks. The confluent growth outside the zone of inhibition was harvested with an inoculation loop and subcultured every 2 weeks until the strain became completely resistant.
Etest assay showed MICs that ranged from 0.004 to 0.125 mg/liter for pradofloxacin and 0.064 to 0.50 for enrofloxacin (Table 1) . Disc diffusion assay was used to test five isolates (BhHI, Mina Mia, Stray7, Bh94FO73, and Bh95FO101). Following serial passages, pradofloxacin remained more active than did enrofloxacin or azithromycin against these five B. henselae isolates (Fig. 1) . For five other isolates tested only with pradofloxacin and enrofloxacin discs, the activity of pradofloxacin was also higher. For BhHI (Fig. 1a) and BhFO2112 isolates, enrofloxacin was active until the fifth passage (diameter of inhibition decreased from 40 mm to Ͻ6 mm), and pradofloxacin was active until the seventh passage (diameter of inhibition decreased from 50 mm to Ͻ6 mm for BhHI and from 40 mm to Ͻ6 mm for BhFO2112). For the Bh95FO101 isolate, enrofloxacin was active until the fifth passage (diameter of inhibition decreased from 30 mm to Ͻ6 mm), whereas pradofloxacin was active until the sixth passage (diameter of inhibition decreased from 40 mm to Ͻ6 mm). For Stray7 (Fig.  1b) and BhFO2221 isolates, enrofloxacin was active until the sixth passage (diameter of inhibition decreased from 40 mm to Ͻ6 mm), and pradofloxacin was active until the eighth passage (diameter of inhibition decreased from 48 mm to Ͻ6 mm for the Stray7 isolate and from 50 mm to Ͻ6 mm for the BhFO2221 isolate). Two B. henselae isolates (Mina Mia and Bh94FO73) had the same susceptibility pattern to both fluoroquinolones until the eighth and fifth passages, respectively. For another two isolates (BhFO1946 and BhFO3021), both fluoroquinolones were active until the sixth passage.
Pradofloxacin was the most active antimicrobial compound tested in our study. Based upon data derived from a single clinical trial in which azithromycin was used to treat patients with classical cat scratch disease, this antibiotic gained favor for the treatment of Bartonella infections in human and veterinary medicine (8) . Interestingly, azithromycin was the least active of the three antibiotics tested. For all five B. henselae isolates tested in our study, azithromycin was active only until the second passage. In a prospective, randomized, doubleblind, and placebo-controlled study that addressed antibiotic treatment of cat scratch disease performed by Bass et al. (2), azithromycin taken orally for 5 days was considered to be effective in decreasing lymph node size within the first 4 weeks following therapy. However, enlargement of new lymph nodes or an increase in size of the original lymph node occurred in some study subjects despite azithromycin therapy. Our in vitro results might explain relapses or treatment failures observed in vivo when using azithromycin for the treatment of Bartonellarelated infections.
A few case reports have described the effective treatment of Bartonella infections with fluoroquinolones (7). Figure 1 provides a comparison of the gradual decrease in diameter of growth inhibition (in mm) in the presence of pradofloxacin, enrofloxacin, and azithromycin discs for B. henselae isolate BhHI (Fig. 1a) and for Stray7 (Fig. 1b) . This figure also demonstrates enhanced in vitro activity of pradofloxacin compared to those of the other antibiotics. Standards for testing are not available for the evaluation of Bartonella spp. for any drug. Nevertheless, all the isolates from this study would be considered "susceptible" to enrofloxacin, using the breakpoint for other bacteria.
In conclusion, pradofloxacin, as an expanded-spectrum fluoroquinolone, has enhanced antimicrobial activity against B. henselae isolates. In contrast, the recommendation to use azithromycin for the treatment of B. henselae infections in veterinary and perhaps human medicine should be reassessed.
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This study was funded by Bayer HealthCare AG. As a postdoctoral fellow in the Intracellular Pathogens Research Laboratory, salary support for S.B. was provided by Bayer Animal Health. Bayer scientists were not involved in the design of the study or in the laboratory testing of the isolates. E.B.B. and M.G.P. have received consulting fees from Bayer Animal Health and have received honoraria for speaking at conferences sponsored by Bayer Animal Health. henselae growth inhibition (mm) around the pradofloxacin, enrofloxacin, and azithromycin discs as determined by the diffusion assay. (a) For Bartonella henselae isolate BhHI, enrofloxacin was active until the fifth passage, and pradofloxacin was active until the seventh passage; however, azithromycin was active only until the second passage. (b) For Bartonella henselae isolate Stray7, enrofloxacin was active until the sixth passage, and pradofloxacin was active until the eighth passage; however, as with isolate BhHI, azithromycin was active only until the second passage.
